Virtually all commentary from the good Dr T point to generating a TO and as such building as much value as possible asap. Whether the TO is “now” or after the 24 weeks of the Healey trial will in my mind be determined by value creation from the other neuro pre clinical work and the quantum of any early TO offers.
Can’t see a partnering offering much advantage to SH assuming PAA remain funded. Not here for dividends.
Ann: AGM Date & Director Nominations Closing Date for AGM, page-12
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $98.34M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.5¢ | $86.20K | 429.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 67508 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 36444 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |